Methods of treating cerebral edema
View Patent ↗The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.
1. A method of treating or controlling cytotoxic cerebral edema comprising administering to a patient in need thereof an effective amount of
in free or pharmaceutically acceptable salt form.
2. The method of claim 1 , wherein the cytotoxic cerebral edema is consequent to a trauma, a stroke, a glioma, meningitis, acute mountain sickness, an epileptic seizure, an infection, a metabolic disorder, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis.
3. The method of claim 1 , wherein the cytotoxic cerebral edema is consequent to an abscess, eclampsia, Creutzfeldt-Jakob disease, or lupus cerebritis.
4. The method of claim 1 , wherein the cytotoxic cerebral edema is consequent to microgravity exposure, radiation exposure, or an invasive central nervous system procedure.
5. The method of claim 4 , wherein the invasive central nervous system procedure is neurosurgery, an endovascular clot removal, a spinal tap, an aneurysm repair, or deep brain stimulation.
6. The method of claim 1 , wherein the cytotoxic cerebral edema is consequent to a stroke.
7. The method of claim 1 , wherein the cytotoxic cerebral edema is consequent to a head trauma.
8. The method of claim 1 , wherein the cytotoxic cerebral edema is consequent to an ischemic stroke.
9. The method of claim 1 , wherein the cytotoxic cerebral edema is consequent to a traumatic brain injury.
10. The method of claim 1 , wherein the cytotoxic cerebral edema is consequent to a middle cerebral artery stroke.
11. The method of claim 1 , wherein the cytotoxic cerebral edema is consequent to hypoxia.
12. The method of claim 11 , wherein the hypoxia is caused by cardiac arrest or other interruption of blood perfusion to the brain.
13. The method of claim 11 , wherein the hypoxia is caused by a stroke.
14. The method of claim 1 , wherein the patient has suffered a stroke or head injury within 12 hours of commencing treatment.
15. The method of claim 1 , wherein the patient has suffered a stroke or head injury within 6 hours of commencing treatment.
16. The method of claim 1 , wherein the patient has suffered a stroke or head injury within 3 hours of commencing treatment.
17. The method of claim 14 , wherein the patient has suffered a stroke within 12 hours of commencing treatment.
18. The method of claim 15 , wherein the patient has suffered a stroke within 6 hours of commencing treatment.
19. The method of claim 16 , wherein the patient has suffered a stroke within 3 hours of commencing treatment.